磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展  

Progress in research of association between phosphodiesterase 5 inhibitors and cancer incidence

作　　者：游以勒 王胜锋[1] You Yile;Wang Shengfeng(Key Laboratory of Epidemiology of Major Diseases,Ministry of Education/Department of Epidemiology and Biostatistics,School of Public Health,Peking University,Beijing 100191,China)

机构地区：[1]北京大学公共卫生学院流行病与卫生统计学系/重大疾病流行病学教育部重点实验室,北京100191

出　　处：《中华流行病学杂志》2023年第9期1486-1490,共5页Chinese Journal of Epidemiology

基　　金：国家重点研发计划(2022YFC3602900);国家自然科学基金(82173616)。

摘　　要：伴随磷酸二酯酶5抑制剂(PDE5Is)用药数量的逐年增加,大量人群研究提示PDE5Is与特定肿瘤发病风险存在潜在关联。本文针对PDE5Is与各种肿瘤发病风险关联及机制研究进行系统梳理,已有研究进行Meta分析,结果显示,使用PDE5Is可能与黑色素瘤(RR=1.11,95%CI:1.02~1.22)、基底细胞癌(RR=1.16,95%CI:1.13~1.20)发病风险增加相关,鳞状细胞癌结果尚不一致,与前列腺癌(OR=0.71,95%CI:0.40~1.29)无统计学关联,对结直肠癌(RR=0.85,95%CI:0.76~0.95)可能具有预防作用。建议未来针对现有研究的经验及不足开展进一步深入探索。With the increased use of phosphodiesterase 5 inhibitors(PDE5Is)over the past years,several population based studies have suggested a potential association between PDE5Is and the risk for specific cancers.This paper systematically summarizes the current status of relatedstudies.Meta-analyses on current research indicated that the use of PDE5Is might be associated with the increased risk for melanoma(RR=1.11,95%CI:1.02-1.22)and basal cell carcinoma(RR=1.16,95%CI:1.13-1.20),but not for prostate cancer(OR=0.71,95%CI:0.40-1.29),and might have chemoprophylaxis effect on colorectal cancer(RR=0.85,95%CI:0.76-0.95).However,results of squamous cell carcinoma were still inconsistent.Further exploration based on the experience and limitations of current research is suggested.

关 键 词：磷酸二酯酶5抑制剂 肿瘤 发病风险 关联研究 机制 

分 类 号：R730[医药卫生—肿瘤]